<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01611870</url>
  </required_header>
  <id_info>
    <org_study_id>HRC-1119-AVAPSAECOPD-SS</org_study_id>
    <nct_id>NCT01611870</nct_id>
  </id_info>
  <brief_title>AVAPS-AE Algorithm in Chronic Obstructive Pulmonary Disease (COPD)Patients</brief_title>
  <acronym>AVAPS-AE COPD</acronym>
  <official_title>Engineering Validation of the AVAPS-AE Algorithm in Chronic Obstructive Pulmonary Disease (COPD)Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philips Respironics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philips Respironics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the performance of AVAPS AE therapy in COPD patients
      during nocturnal ventilation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in TCO2 measurement from baseline to 2 weeks post AVAPS-AE mode of therapy and change in TCO2 measurement from baseline to 6 weeks post AVAP-AE mode of therapy</measure>
    <time_frame>Baseline study, 2 week study and after 6 weeks of therapy</time_frame>
    <description>The baseline bilevel sleep study data and the AVAPS-AE sleep study data (from Baseline, 2 week and 6 week visits) will be analyzed to ascertain adequate control of nocturnal ventilation via mean overnight TcCO2 measurements.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Actigraphy</measure>
    <time_frame>2 weeks prior to the Baseline Sleep study</time_frame>
    <description>Monitors activity during the day and sleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six Minute Walk test</measure>
    <time_frame>Baseline, 2 week and 6 week measurements</time_frame>
    <description>Six minute walk test will assess total distance walked, pre/post Borg dyspnea scale ratings and overall fatigue ratings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spirometry</measure>
    <time_frame>Baseline, 2 week and 6 week measurements</time_frame>
    <description>Spirometry will assess flow rates for breathing manuevers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nocturnal Capnography (TcC02)</measure>
    <time_frame>Baseline, 2 week and 6 week measurements</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nocturnal oximetry (Sp02)</measure>
    <time_frame>Baseline, 2 week and 6 week measurements</time_frame>
    <description>oximetry testing to monitor oxygen saturation during sleep studies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Sleep Log</measure>
    <time_frame>During the initial 14 days of AVAPS-AE therapy at home</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe Respiratory Insufficiency Questionnaire</measure>
    <time_frame>Baseline, 2 week and 6 week visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD Assessment Test- CAT</measure>
    <time_frame>Baseline, 2 week and 6 week visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRC Dyspnea Questionnaire</measure>
    <time_frame>Baseline, 2 week and 6 week visits</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Single arm study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AVAPS-AE</intervention_name>
    <description>AVAPS-AE is the experimental ventilation mode of therapy in this study that includes a combination of already cleared therapy attributes.</description>
    <arm_group_label>Single arm study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AVAPS-AE mode of ventilator therapy</intervention_name>
    <description>All participants will use the study device in the titrated to the AVAPS-AE mode of ventilator therapy for six weeks of home use.</description>
    <arm_group_label>Single arm study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than or equal to 18 years

          -  Diagnosis of COPD

          -  Currently using a Bilevel device

          -  Documentation of medical stability by PI

        Exclusion Criteria:

          -  Subjects, who are acutely ill, medically complicated or who are medically unstable

          -  Subjects in whom PAP therapy is otherwise medically contraindicated

          -  Subjects who have had surgery of the upper airway, nose, sinus, or middle ear within
             the previous 90 days

          -  Subjects with untreated, non-OSA sleep disorders, including but not limited to;
             insomnia, periodic limb movement syndrome, or restless leg syndrome (PLMI &gt; 10)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Hart, PhD, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guys and St. Thomas' NHS Foundation &amp; Trust Kings College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NIHR Comprehensive Biomedical Research Center</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Hart, PhD, MRCP</last_name>
      <phone>020 7188 7608</phone>
      <email>Nicholas.Hart@gstt.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2012</study_first_submitted>
  <study_first_submitted_qc>June 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2012</study_first_posted>
  <last_update_submitted>June 4, 2012</last_update_submitted>
  <last_update_submitted_qc>June 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

